JPMorgan analyst Jessica Fye raised the firm’s price target on BeOne Medicines (ONC) to $321 from $317 and keeps an Overweight rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeiGene’s Robust Oncology Pipeline and Strategic Developments Justify Buy Rating with $300 Price Target
- Beigene’s Promising Phase 1 Study on BGB-21447 for Metastatic Breast Cancer
- BeiGene’s Zanubrutinib Study: A Potential Game-Changer for B-Cell Lymphoma Treatment
- Beigene’s Zanubrutinib Study: A Potential Game-Changer in Nephropathy Treatment?
- BeiGene’s Promising Phase 3 Study on Lung Cancer Treatment